FDA product approval
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Cognitive · compound · checked 2026-10-09
Noopept (Omberacetam)
Noopept (Omberacetam) is listed here as a compound. Synthetic dipeptide-derived research nootropic; it is not Semax or Selank. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use Noopept (Omberacetam) or how much to take.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- not established
- Compounding
- not established
- Research
- investigational
- Sport
- unknown
What is Noopept (Omberacetam)?
Other names in the library: omberacetam, Noopept Spray 150 mg (1.5mg/spray), Noopept. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 1.5 mg, 150 mg. A seller title is a listing. It does not prove the vial matches a paper.
Synthetic dipeptide-derived research nootropic; it is not Semax or Selank.
Regulatory status, dated 2026-10-09
Compounding
not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.
Research
investigational. Rat neurophysiology experiments in the cited primary study.
Sport
unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.
What the cited papers actually measured
We mark the cited papers as C for Preclinical models and an open prospective report in 60 post-stroke patients. and Reported cognitive-test improvement in a clinical observation study.. Open prospective human observations with a reported comparison group exist; lack of blinding and unclear allocation limit inference about healthy-person benefit, long-term safety or supplier equivalence. The study measured changes in transcallosal evoked potentials. The cited result is animal evidence, not a verified benefit for healthy adult cognition or a nasal commercial preparation. An open prospective study reported improved cognitive-test performance compared with controls. Open study with a reported comparison group, unclear allocation and no blinding. The abstract describes different treatment and assessment durations. It does not establish benefit in healthy adults. Risks on the record: Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
We mark the cited papers as C. That is our label for how strong those papers are. It does not say the compound works.
preclinical
The study measured changes in transcallosal evoked potentials.
Rat neurophysiology experiments in the cited primary study. The cited result is animal evidence, not a verified benefit for healthy adult cognition or a nasal commercial preparation.
human-observation
An open prospective study reported improved cognitive-test performance compared with controls.
60 people with post-stroke cognitive impairment. Open study with a reported comparison group, unclear allocation and no blinding. The abstract describes different treatment and assessment durations. It does not establish benefit in healthy adults.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.
Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.
U-100 math for listed Noopept (Omberacetam) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 1.5 mg | 15 | 7.5 | 5 |
| 150 mg | 1500 | 750 | 500 |
Risks and mix-ups already on the record
- Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
- No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
- No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.
People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.
Sources
- Noopept primary study · PMID 12109288 · checked 2026-10-09
- Noopept: open prospective post-stroke report (2011) · checked 2026-10-09
Questions people ask
Is Noopept (Omberacetam) FDA-approved?
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Does PepBear pick an amount of Noopept (Omberacetam)?
The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.
Related cards
Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.